Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland and over the Northern Territory the ribbon has been cut on the new Sacco System development site in Brisbane – Australia. Sacco System is a company with strong values, born over 150 years ago and still owned by the Verga Family, starting with the rennet production, nowadays is recognized worldwide as a biotech excellence in the production if enzyme, cultures, probiotics, postbiotics and LPB’s.
“Our Brisbane laboratories are designed to deliver early development for our fermentations. We aim to create industrial processes that are robust, reliable and compliant to regulation for a broad variety of microbes. Starting with our in-silico work we can bring all steps of fermentations to a volume of 30L to deliver the information necessary for our larger scale facilities to work effectively ”, said Max Rossetto, Microbial Therapeutics Global Business Development Director.
“Being in Australia opening our development site for Next-gen microorganisms and live biotherapeutics is sensational and absolutely and totally inspirational per se. And working hard to make it became an excellence for Sacco System Group and for the Australian State is what we should be inspired to do in the next years! ” said Viola Verga during her speech during the Grand Opening.
Australia was chosen as the site of our process development related to Next-gen microorganisms and live biotherapeutics for a number of reasons. It is easy set up a business in Australia, a modern, high quality business location with stable government, transparent regulations and which has deep and broad connections with Italy as mentioned by the Consul. This together with the presence of a cluster of microbiome related businesses and an impressive academic sector in Southern Queensland made Brisbane a natural choice for the first Sacco System site in the Asia Pacific region.
Latest News
GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a
Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1
We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved and the challenges ahead…
Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland…
At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici…
List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement…
Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries…
We are proud to announce that Sacco System has made a significant donation in support of Action4Diabetes’ (A4D) mission—a UK-based charity committed to ensuring free access to crucial medical supplies…
This year too, SACCO SYSTEM proudly participates in the Deploy Your Talents (DYT) project, promoted by the Fondazione Sodalitas, with the patronage of the Municipality of Milan…
Sacco System is pleased to announce that the new website ingredients.saccosystem.com is online.
INgredients is the project…
Join us at the 16th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health – IPC2023, taking place from June 20-22, 2023…
SACCO SYSTEM at Vitafoods, May 9-11, in Geneva at Palexpo, Route François-Peyrot 30, 1218 Le Grand-Saconnex, Switzerland…